Schlich represented Opponent 1 and is pleased to report as follows. The proceedings focused on the issue of priority right under the Paris Convention, a treaty providing a harmonized system for international patent priority rights. After nearly two days of...
Introduction The Cancer Immunotherapy Pilot Program, also known as “Patents 4 Patients”, makes certain US patent applications relating to cancer immunotherapy eligible for special status and examination with the goal of completing prosecution within 12...
Background Article 6(2) of the EU Biotech Directive excludes uses of human embryos for industrial or commercial purposes from patentability[1]. This exclusion does not affect inventions for therapeutic or diagnostic purposes which are applied to the human embryo and...
Introduction In decisions G 2/12 (“Broccoli II”) and G 2/13 (“Tomatoes II”), the Enlarged Board of Appeal (EBA) of the European Patent Office (EPO) found that plants and products thereof, e.g. seeds and fruits, are patentable. This is the case...
Executive Summary / Practice Points Stem cell technologies promise to be the next transformative medical technology offering therapies for conditions and diseases that are currently beyond medical science by creating replacement or supplementary tissues for a patient....
Recent Comments